Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study.

Détails

ID Serval
serval:BIB_882998311C4F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study.
Périodique
Rare tumors
Auteur(s)
Zwahlen D.R., Schick U., Bolukbasi Y., Thariat J., Abdah-Bortnyak R., Kuten A., Igdem S., Caglar H., Ozsaran Z., Loessl K., Khanfir K., Villette S., Vees H.
ISSN
2036-3605 (Print)
ISSN-L
2036-3605
Statut éditorial
Publié
Date de publication
28/06/2016
Peer-reviewed
Oui
Volume
8
Numéro
2
Pages
6052
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Uterine carcinosarcomas (UCS) are rare tumors. Consensus regarding therapeutic management in non-metastatic disease is lacking. This study reports on outcome and predictive factors when using postoperative radiotherapy. We analyzed a retrospective analysis in 124 women treated between 1987-2007 in the framework of the Rare-Cancer-Network. Median follow-up was 27 months. Postoperative pelvic EBRT was administered in 105 women (85%) and 92 patients (74%) received exclusive or additional vaginal brachytherapy. Five-year overall survival (OS), disease-free survival (DFS), cancer specific survival (CSS) and locoregional control (LRC) were 51.6% (95% CI 35-73%), 53.7% (39-71%), 58.6% (38-74%) and 48% (38-67%). Multivariate analysis showed that external beam radiation therapy (EBRT) >50Gy was an independent prognostic factor for better OS (P=0.03), CSS (P=0.02) and LRC (P=0.01). Relative risks (RR) for better OS (P=0.02), DFS (P=0.04) and LRC (P=0.01) were significantly associated with younger age (≤60 years). Higher brachytherapy (BT)-dose (>9Gy) improved DFS (P=0.04) and LRC (P=0.008). We concluded that UCS has high systemic failure rate. Local relapse was reduced by a relative risk factor of over three in all stages of diseases when using higher doses for EBRT and brachytherapy. Postoperative RT was most effective in UCS stage I/II-diseases.
Mots-clé
Carcinosarcoma, brachytherapy, radiotherapy, toxicity, uterine malignancies
Pubmed
Web of science
Open Access
Oui
Création de la notice
18/10/2019 17:33
Dernière modification de la notice
19/10/2019 5:26
Données d'usage